Pharma R&D Today

Ideas and Insight supporting all stages of Drug Discovery & Development

Select category
Search this blog

Tackling Unmet Needs with a Proprietary Platform

Posted on November 22nd, 2018 by in Pharma R&D

Since our founding back in 2006, LegoChem Biosciences (LCB) has focused on the research and development of anti-biotic, anti-coagulant, anti-fibrosis and Antibody-Drug Conjugate (ADC) therapeutics based on our proprietary platform technology, LegoChemistry™ & Conjuall™. LCB is comprised of researchers who have varied backgrounds and R&D experiences, including the development of Factive, the first US FDA-approved drug developed in Korea. Continue reading “Tackling Unmet Needs with a Proprietary Platform” »